Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
NCT05964335 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Trevi Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 6, 2024
- Completion date
- April 24, 2025
- Enrollment
- 165 (actual)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.